
Sign up to save your podcasts
Or


We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
By Erin Harris4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn

3,479 Listeners

756 Listeners

158 Listeners

817 Listeners

113,488 Listeners

10,345 Listeners

338 Listeners

6,578 Listeners

5,657 Listeners

6,450 Listeners

87 Listeners

5,592 Listeners

10,959 Listeners

16 Listeners

1,476 Listeners